SBPH News and Press, Spring Bank From 07/30/20

Spring Bank Pharmaceuticals ( SBPH -10.1% ) and F-star Therapeutics have agreed to merge , and will begin operating under the name F-star Therapeutics. More news on: Spring Bank Pharmaceuticals, Inc., Merger & acquisition news, Healthcare stocks news, Stocks on the move, Read mo...

FSD Pharma (NASDAQ: HUGE ) +130% . on decision to surrender health Canada licenses for subsidiary FV Pharma. More news on: FSD Pharma Inc., Kandi Technologies Group, Inc., Edesa Biotech, Inc., Stocks on the move, , Read more ...

Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programs Combined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate contingent value rights re...

Gainers:  Eastman Kodak (NYSE: KODK ) +319% . More news on: Eastman Kodak Company, Tupperware Brands Corporation, Sonoma Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Boxlight (NASDAQ: BOXL )   -27%  after  pricing  equity offering. More news on: Boxlight Corporation, Global Eagle Entertainment Inc., Sypris Solutions, Inc., Stocks on the move, , Read more ...

-    Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) -  ...

The following slide deck was published by Spring Bank Pharmaceuticals, Inc. in conjunction with this Read more ...

HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be par...

HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will ...

Spring Bank Pharma (NASDAQ: SBPH ): Q1 GAAP EPS of -$0.49 misses by $0.29 . More news on: Spring Bank Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...